利巴维林治疗慢性C型肝炎的治疗方法
O Reichard1, J Andersson, R Schvarcz
1Department of Infectious Diseases, Karolinska Institute, Danderyds Hospital, Stockholm, Sweden.
Lancet (London, England)
|May 4, 1991
概括
口服里巴维林在治疗慢性C型肝炎感染方面表现有前途. 这项试点研究发现,治疗期间肝酶显著下降,并有轻微的副作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性型肝炎病毒 (HCV) 感染是全球重要的健康问题.
- 慢性型肝炎目前的治疗选择有局限性.
- 非A,非B型肝炎,现在被称为C型肝炎,需要有效的治疗策略.
研究的目的:
- 评估口服里巴维林作为治疗慢性型肝炎的疗效和安全性.
- 评估瑞巴维林对慢性型肝炎患者肝酶水平的影响.
- 确定利巴维林作为C型肝炎的口服治疗剂的潜力.
主要方法:
- 试点研究涉及10名活检证明慢性非A,非B型肝炎的患者.
- 患者每天服用1000-1200毫克口服里巴维林,持续12周.
- 在治疗前,治疗期间和治疗后监测血清氨酸胺转移酶 (ALT) 水平.
主要成果:
- 在利巴维林治疗12周后,观察到ALT水平中位数显著下降 (p < 0.005).
- 在治疗后6周内,ALT水平恢复到治疗前的度.
- 报告的副作用是轻微的,在停止利巴维林后可以逆转.
结论:
- 口服里巴维林显示出作为慢性型肝炎有效治疗的潜力.
- 利巴维林是第一种口服药物,在治疗慢性型肝炎方面表现有前途.
- 需要在受控试验中进行进一步的研究,可能将利巴维林与干扰素α结合起来.
相关概念视频
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...


